scholarly journals Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors

2007 ◽  
Vol 13 (11) ◽  
pp. 1324-1337 ◽  
Author(s):  
Yago Nieto ◽  
Azucena Aldaz ◽  
José Rifón ◽  
Javier Pérez-Calvo ◽  
Ana Zafra ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Rate ◽  
Pharmacokinetic Study ◽  
Progenitor Cell ◽  
Fixed Dose ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor ◽  
Fixed Dose Rate ◽  
Cell Support

Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies

2000 ◽  
Vol 18 (5) ◽  
pp. 947-947 ◽  
Author(s):  
Ivana N. M. Micallef ◽  
Debra M. Lillington ◽  
John Apostolidis ◽  
John A. L. Amess ◽  
Michael Neat ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Progenitor Cell ◽  
Myelogenous Leukemia ◽  
Hematopoietic Progenitor Cell ◽  
High Dose ◽  
High Dose Therapy ◽  
Hematopoietic Progenitor ◽  
Acute Myelogenous ◽  
Cell Support

PURPOSE: To evaluate the incidence of and risk factors for therapy-related myelodysplasia (tMDS) and secondary acute myelogenous leukemia (sAML), after high-dose therapy (HDT) with autologous bone marrow or peripheral-blood progenitor-cell support, in patients with non-Hodgkin’s lymphoma (NHL). PATIENTS AND METHODS: Between January 1985 and November 1996, 230 patients underwent HDT comprising cyclophosphamide therapy and total-body irradiation, with autologous hematopoietic progenitor-cell support, as consolidation of remission. With a median follow-up of 6 years, 27 (12%) developed tMDS or sAML. RESULTS: Median time to development of tMDS or sAML was 4.4 years (range, 11 months to 8.8 years) after HDT. Karyotyping (performed in 24 cases) at diagnosis of tMDS or sAML revealed complex karyotypes in 18 patients. Seventeen patients had monosomy 5/5q−, 15 had −7/7q−, seven had −18/18q−, seven had −13/13q−, and four had −20/20q−. Twenty-one patients died from complications of tMDS or sAML or treatment for tMDS or sAML, at a median of 10 months (range, 0 to 26 months). Sixteen died without evidence of recurrent lymphoma. Six patients were alive at a median follow-up of 6 months (range, 2 to 22 months) after diagnosis of tMDS or sAML. On multivariate analysis, prior fludarabine therapy (P = .009) and older age (P = .02) were associated with the development of tMDS or sAML. Increased interval from diagnosis to HDT and bone marrow involvement at diagnosis were of borderline significance (P = .05 and .07, respectively). CONCLUSION: tMDS and sAML are serious complications of HDT for NHL and are associated with very poor prognosis. Alternative strategies for reducing their incidence and for treatment are needed.

Results of a phase I study of fixed dose rate gemcitabine /irinotecan (FIGI)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2112-2112
Author(s):  
T. Ryan ◽  
H. Hochster ◽  
J. Escalon ◽  
F. M. Muggia
Keyword(s):  
Phase I ◽  
Dose Rate ◽  
Phase I Study ◽  
Fixed Dose ◽  
Fixed Dose Rate

Phase I study of fixed-dose rate (FDR) gemcitabine with capecitabine in advanced solid malignancies

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 13509-13509
Author(s):  
S. Attia ◽  
J. Eickhoff ◽  
K. D. Holen ◽  
H. Bailey ◽  
D. Alberti ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Rate ◽  
Phase I Study ◽  
Fixed Dose ◽  
Solid Malignancies ◽  
Fixed Dose Rate

scholarly journals A Phase I–II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

2010 ◽  
Vol 50 (3) ◽  
pp. 448-454 ◽  
Author(s):  
Ulrik Lassen ◽  
Lars Henrik Jensen ◽  
Morten Sorensen ◽  
Kristoffer S. Rohrberg ◽  
Zaza Ujmajuridze ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Rate ◽  
Dose Escalation ◽  
Fixed Dose ◽  
Dose Escalation Study ◽  
Fixed Dose Rate

High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.

1996 ◽  
Vol 14 (5) ◽  
pp. 1463-1472 ◽  
Author(s):  
S M Stemmer ◽  
P J Cagnoni ◽  
E J Shpall ◽  
S I Bearman ◽  
S Matthes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Poor Prognosis ◽  
Progenitor Cell ◽  
Multiorgan Failure ◽  
Metastatic Breast ◽  
Hematopoietic Progenitor Cell ◽  
High Dose ◽  
Hematopoietic Progenitor ◽  
Cell Support

PURPOSE To determine the maximal-tolerated dose (MTD) of paclitaxel in combination with high-dose cyclophosphamide (CPA) and cisplatin (cDDP) followed by autologous hematopoietic progenitor-cell support (AHPCS). PATIENTS AND METHODS Forty-nine patients with poor-prognosis breast cancer, non-Hodgkin's lymphoma (NHL), or ovarian cancer were treated with escalating doses of paclitaxel infused over 24 hours, followed by CPA (5,625 mg/m2 intravenously over 1 hour in three divided doses) and cDDP (165 mg/m2 intravenously as a continuous infusion over 72 hours) and AHPCS. Pharmacokinetic measurements for each drug were performed. RESULTS Dose-limiting toxicities were encountered in two patients at 825 mg/m2 of paclitaxel; one patient died of multiorgan failure that involved the lung, CNS, and kidneys, and the other developed grade 3 respiratory, CNS, and renal toxicity, which resolved. The MTD of this combination was determined to be paclitaxel 775 mg/m2, CPA 5,625 mg/m2, and cDDP 165 mg/m2 followed by AHPCS. Sensory polyneuropathy and mucositis were prominent toxicities, but both were reversible and tolerable. The pharmacokinetics of paclitaxel correlated significantly with the severity of mucositis (P < .001) and peripheral neuropathy (P < .00004). Eighteen of 33 patients (54%) with measurable, heavily pretreated metastatic breast cancer achieved a partial response (PR). Responses were also observed in patients with NHL (four of five patients) and ovarian cancer (two of two). CONCLUSION It is possible to escalate the dose of paclitaxel to 775 mg/m2 in combination with 5,625 mg/m2 of CPA, 165 mg/m2 of cDDP, and AHPCS. An encouraging response rate in poor-prognosis patients with breast cancer, NHL, and ovarian cancer warrants further study.

scholarly journals Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study

2006 ◽  
Vol 94 (12) ◽  
pp. 1797-1802 ◽  
Author(s):  
A López-Pousa ◽  
R Losa ◽  
J Martín ◽  
J Maurel ◽  
J Fra ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase I ◽  
Dose Rate ◽  
Soft Tissue Sarcomas ◽  
Fixed Dose ◽  
Fixed Dose Rate ◽  
Fixed Dose Rate Infusion ◽  
Rate Infusion
Sign in / Sign up

Export Citation Format

Share Document